Who are lithium or lamotrigine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lithobid, Tegretol, CARBAMAZEPINE, carbamazepine ER, Tegretol®, Escitalopram, venlafaxine, lithium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lithium-or-lamotrigine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

lithium or lamotrigine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

lithium or lamotrigine (lithium or lamotrigine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mood stabilizer. Area: Psychiatry.

phase 3 Mood stabilizer Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

lithium or lamotrigine (lithium or lamotrigine) — University of Aarhus. Lithium is a mood stabilizer that works by affecting the levels of certain neurotransmitters in the brain, such as serotonin and dopamine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
lithium or lamotrigine TARGET	lithium or lamotrigine	University of Aarhus	phase 3	Mood stabilizer
Lithobid	lithium carbonate	Generic (multiple manufacturers)	marketed	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
Tegretol	carbamazepine	Novartis AG (originally Geigy)	marketed	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
CARBAMAZEPINE	CARBAMAZEPINE		marketed	Mood Stabilizer [EPC]		1968-01-01
carbamazepine ER	carbamazepine-er	Pfizer Inc.	marketed	Mood Stabilizer [EPC]
Tegretol®	Tegretol®	University of Malaya	marketed	Anticonvulsant; mood stabilizer	Voltage-gated sodium channels
Escitalopram, venlafaxine, lithium	Escitalopram, venlafaxine, lithium	K. Lieb	marketed	Antidepressant combination (SSRI + SNRI + mood stabilizer)	Serotonin transporter (SERT), norepinephrine transporter (NET), and lithium-responsive intracellular signaling pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-11-10 — Tegretol · 9770407 · Formulation · US
2028-11-10 — Tegretol · 9629797 · Method of Use · US
2029-03-13 — Tegretol · 9750822 · Formulation · US
2029-03-13 — Tegretol · 7635773 · Formulation · US
2029-03-13 — Tegretol · 8410077 · Formulation · US
2033-02-27 — Tegretol · 9493582 · Formulation · US
2040-01-31 — Tegretol · 11529357 · Formulation · US

Sponsor landscape (Mood stabilizer class)

Shanghai Mental Health Center · 2 drugs in this class
Generic (multiple manufacturers) · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class
AstraZeneca · 1 drug in this class
University of Aarhus · 1 drug in this class
University of Milan · 1 drug in this class
Weill Medical College of Cornell University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). lithium or lamotrigine — Competitive Intelligence Brief. https://druglandscape.com/ci/lithium-or-lamotrigine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing